Utility values among patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line treatment with pazopanib (PZ) and sunitinib (SU).

被引：3
|
作者：
Hagiwara, May
Park, Jinhee
Delea, Thomas E.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e21068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21068
引用
收藏
页数：2
相关论文
共 50 条
  • [41] COSTS ASSOCIATED WITH HEALTH CARE RESOURCE USE IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH PAZOPANIB VERSUS SUNITINIB
    Hackshaw, M. D.
    Hansen, R. N.
    Nagar, S. P.
    Arondekar, B.
    Deen, K. C.
    Sullivan, S. D.
    Ramsey, S. D.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A77 - A78
  • [42] Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Laguna, M. Pilar
    [J]. JOURNAL OF UROLOGY, 2017, 197 (03): : 603 - 603
  • [43] COST MINIMIZATION ANALYSIS OF USING PAZOPANIB IN FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Romero Prada, M. E.
    Celis, S.
    Alfonso Quinones, P. A.
    Acero, G.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A739 - A739
  • [44] Broad immunomodulating effect of first-line Pazopanib in metastatic renal cell carcinoma patients
    Verzoni, E.
    Cova, A.
    Squarcina, P.
    De Cecco, L.
    Rinchai, D.
    Bedognetti, D.
    Grassi, P.
    Ratta, R.
    Procopio, G.
    Rivoltini, L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [45] Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients
    Verzoni, E.
    De Cecco, L.
    Dugo, M.
    Rinchai, D.
    Bedognetti, D.
    Grassi, P.
    Ratta, R.
    Cova, A.
    Squarcina, P.
    Huber, V.
    Montone, R.
    Sorrentino, M.
    Procopio, G.
    Rivoltini, L.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [46] Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su)
    Berger, Raanan
    Keizman, Daniel
    Ish-Shalom, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Pili, Roberto
    Boursi, Ben
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] SEQUENTIAL TARGETED THERAPY FOLLOWING PAZOPANIB (PZ) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CANCER (MRCC): EFFICACY AND TOXICITY
    Pons Valladares, F.
    Choueiri, T. K.
    Hutson, T. E.
    Powles, T. B.
    Porta, C.
    Bracarda, S.
    Lampron, M. E.
    Cerbone, L.
    Sternberg, C. N.
    Bellmunt, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 278 - 278
  • [48] Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
    Bianconi, Maristella
    Faloppi, Luca
    Loretelli, Cristian
    Zizzi, Antonio
    Giampieri, Riccardo
    Bittoni, Alessandro
    Andrikou, Kalliopi
    Del Prete, Michela
    Burattini, Luciano
    Montironi, Rodolfo
    Scartozzi, Mario
    Cascinu, Stefano
    [J]. ONCOTARGET, 2016, 7 (25) : 37599 - 37607
  • [49] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [50] Efficacy and safety of sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC) and lung metastases (mets) only at baseline
    Shinohara, Nobuo
    Akaza, Hideyuki
    Tomita, Yoshihiko
    Yuasa, Takeshi
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Ozono, Seiichiro
    Mugiya, Soichi
    Miki, Tsuneharu
    Uemura, Hirotsugu
    Nonomura, Norio
    Takahashi, Masayuki
    Hasegawa, Yoshihiro
    Ueda, Eiji
    Shibata, Atsushi
    Kawai, Norisuke
    Naito, Seiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345